Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2020 > Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Read also

FDA Clears Gain Therapeutics to Launch Global Parkinson's Phase 2 Trial

FDA Clears Gain Therapeutics to Launch Global Parkinson's Phase 2 Trial

Gain Therapeutics received FDA IND clearance to launch a multi-continent Phase 2 clinical trial of GT-02287, an oral small molecule for Parkinson's.

MIRA Pharmaceuticals Reports Promising SKNY-1 Data for Obesity Tracking

MIRA Pharmaceuticals Reports Promising SKNY-1 Data for Obesity Tracking

MIRA Pharmaceuticals shared new preclinical data for SKNY-1, an oral candidate demonstrating strong brain penetration and once-daily dosing potential.

UCLA Wins $7.49M CIRM Grant to Advance Novel Multiple Sclerosis Therapy

UCLA Wins $7.49M CIRM Grant to Advance Novel Multiple Sclerosis Therapy

A UCLA research team led by Dr. Lili Yang secured a $7.49M CIRM grant to transition an engineered NKT cell-based immunotherapy for MS into clinical trials.

Breakthrough HIV Vaccine Candidate Shows Major Promise in Primate Study

Breakthrough HIV Vaccine Candidate Shows Major Promise in Primate Study

An experimental HIV vaccine from LJI and Scripps Research successfully generated broadly neutralizing antibodies in primates, marking a historic milestone.